Design, Synthesis, Biological Evaluation, and Computational Studies of Novel 1,4‐Diketopiperazines as GABA Agonist
Drug Development Research · 2025
DOI: 10.1002/ddr.70136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Mostafa Abd El-Mohsen Anwar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Collage of Pharmaceutical Science and Drug Manufacturing, Misr University for Science and Technology, Giza, Egyp…. Hauptthemen laut MEDLINE: Anticonvulsants, Seizures, Diketopiperazines, GABA Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
A novel series of 1,1‐disubstituted cyclohexane 7a‐e , 8a‐e , and 9a‐e were designed, synthesized, and evaluated for their anticonvulsant activities. Compounds 7c , 8c , 8d , and 9a displayed significant anticonvulsant activity in both maximum electroshock seizure (MES) and pentylenetetrazol (PTZ) induced seizure during the preliminary screening with no neurotoxicity. The phase II quantitative anticonvulsant activity revealed that compound 8c demonstrated the most potent activity as compared to the conventional drugs phenobarbital. The expression of nuclear factor erythroid 2‐related factor‐ antioxidant response element (Nrf2‐ARE) signaling pathways, oxidative stress parameters were also observed. Additionally, histopathological examination of brain of animals treated with compounds 7c , 8c , 8d , and 9a was performed and the results were corroborated the neuroprotective properties. Further neurochemical investigation was performed to unravel the effect of the most active compounds, compounds 7c , 8c , 8d , and 9a demonstrated significant protection by ameliorating GABA levels, which were initially reduced to 61% by PTZ administration, suggesting enhanced GABAergic neurotransmission. Computational parameters including docking analysis on GABAA exhibiting good binding on the active site, Moreover, In silico prediction was carried out indicating that most of compounds have favorable oral bioavailability and BBB permeability they might be viewed as helpful models for future research and derivatization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Chemistry Department, Collage of Pharmaceutical Science and Drug Manufacturing, Misr University for Science and Technology, Giza, Egypt.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
- Department of Pharmacology, National Research Centre, Medical Research and Clinical Studies Institute, Giza, Egypt.
- Neurology Department, Indiana University School of Medicine, Indiana, Indianapolis, USA.
- Department of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
- Department of Physiology, National Organization for Drug Control and Research, Giza, Egypt.
ORCID-Profile: Mostafa Abd El-Mohsen Anwar, Nesma M E Abo El Nasr, Marawan A Elbaset, Omar Ahmed-Farid, Walaa Hamada Abd-Allah
Zitieren
APA
Anwar, M. A. E., Mohammed, E. R., El Moghazy, S. M., Abo El Nasr, N. M. E., Elbaset, M. A., Korany, R. M. S., Ahmed-Farid, O., Ibrahim, I. M., & Abd-Allah, W. H. (2025). Design, Synthesis, Biological Evaluation, and Computational Studies of Novel 1,4‐Diketopiperazines as GABA Agonist. Drug Development Research. https://doi.org/10.1002/ddr.70136
Vancouver
Anwar MAE, Mohammed ER, El Moghazy SM, Abo El Nasr NME, Elbaset MA, Korany RMS, et al. Design, Synthesis, Biological Evaluation, and Computational Studies of Novel 1,4‐Diketopiperazines as GABA Agonist. Drug Development Research. 2025. doi:10.1002/ddr.70136
BibTeX
@article{Anwar2025,
author = {Anwar, Mostafa Abd El-Mohsen and Mohammed, Eman R and El Moghazy, Samir M and Abo El Nasr, Nesma M E and Elbaset, Marawan A and Korany, Reda M S and Ahmed-Farid, Omar and Ibrahim, Ibrahim M and Abd-Allah, Walaa Hamada},
title = {Design, Synthesis, Biological Evaluation, and Computational Studies of Novel 1,4‐Diketopiperazines as GABA Agonist},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70136}
}
EUVIMED